| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J S Kim, C M Park, J A Choi, E Park, H J Tchoe, M Choi, J K Suh, Y H Kim, S H Won, Y C Chung, K Y Bae, S K Lee, S C Park, S H Le. The association between season of birth, age at onset, and clozapine use in schizophrenia. Acta psychiatrica Scandinavica. vol 136. issue 5. 2018-06-05. PMID:28741647. |
the association between season of birth, age at onset, and clozapine use in schizophrenia. |
2018-06-05 |
2023-08-13 |
Not clear |
| J S Kim, C M Park, J A Choi, E Park, H J Tchoe, M Choi, J K Suh, Y H Kim, S H Won, Y C Chung, K Y Bae, S K Lee, S C Park, S H Le. The association between season of birth, age at onset, and clozapine use in schizophrenia. Acta psychiatrica Scandinavica. vol 136. issue 5. 2018-06-05. PMID:28741647. |
this study aimed to determine whether the rate of clozapine use, an indicator of refractoriness in schizophrenia, is associated with the season of birth and age at onset in patients with schizophrenia based on nationwide data. |
2018-06-05 |
2023-08-13 |
Not clear |
| David M Taylo. Clozapine for Treatment-Resistant Schizophrenia: Still the Gold Standard? CNS drugs. vol 31. issue 3. 2018-06-04. PMID:28258419. |
clozapine for treatment-resistant schizophrenia: still the gold standard? |
2018-06-04 |
2023-08-13 |
Not clear |
| Thomas Re Barnes, Verity C Leeson, Carol Paton, Louise Marston, Linda Davies, William Whittaker, David Osborn, Raj Kumar, Patrick Keown, Rameez Zafar, Khalid Iqbal, Vineet Singh, Pavel Fridrich, Zachary Fitzgerald, Hemant Bagalkote, Peter M Haddad, Mariwan Husni, Tim Amo. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness. Health technology assessment (Winchester, England). vol 21. issue 49. 2018-06-04. PMID:28869006. |
when treatment-refractory schizophrenia shows an insufficient response to a trial of clozapine, clinicians commonly add a second antipsychotic, despite the lack of robust evidence to justify this practice. |
2018-06-04 |
2023-08-13 |
Not clear |
| Lama Souaiby, Claire Gauthier, Christine Rieu, Marie-Odile Krebs, Emmanuelle Advenier-Iakovlev, Raphaël Gaillar. Clozapine and long-acting injectable antipsychotic combination: A retrospective one-year mirror-image study. Schizophrenia research. vol 188. 2018-05-30. PMID:28139358. |
to evaluate efficacy and tolerability of the combination of clozapine with an antipsychotic long-acting injectable (lai) in multi-episode patients with schizophrenia or schizoaffective disorder. |
2018-05-30 |
2023-08-13 |
Not clear |
| Nicholas Myles, Hannah Myles, Scott R Clark, Robert Bird, Dan Siskin. Use of granulocyte-colony stimulating factor to prevent recurrent clozapine-induced neutropenia on drug rechallenge: A systematic review of the literature and clinical recommendations. The Australian and New Zealand journal of psychiatry. vol 51. issue 10. 2018-05-28. PMID:28747065. |
clozapine is the most effective medication for treatment-refractory schizophrenia; however, its use is contraindicated in people who have had previous clozapine-induced neutropenia. |
2018-05-28 |
2023-08-13 |
Not clear |
| Lyang Huh, Bong Ju Le. [Efficacy of low-Dose Aripiprazole to Treat Clozapine-Associated Tardive Dystonia in a Patient with Schizophrenia]. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 28. issue 3. 2018-05-25. PMID:28936820. |
clozapine has been used as a treatment option for tdt in patients with schizophrenia. |
2018-05-25 |
2023-08-13 |
Not clear |
| Katalin Tóth, Gábor Csukly, Dávid Sirok, Ales Belic, Ádám Kiss, Edit Háfra, Máté Déri, Ádám Menus, István Bitter, Katalin Monostor. Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics. The international journal of neuropsychopharmacology. vol 20. issue 7. 2018-05-23. PMID:28340122. |
the atypical antipsychotic clozapine is effective in treatment-resistant schizophrenia; however, the success or failure of clozapine therapy is substantially affected by the variables that impact the clozapine blood concentration. |
2018-05-23 |
2023-08-13 |
Not clear |
| Rachel J Suetani, Dan Siskind, Heidi Reichhold, Steve Kisel. Genetic variants impacting metabolic outcomes among people on clozapine: a systematic review and meta-analysis. Psychopharmacology. vol 234. issue 20. 2018-05-22. PMID:28879574. |
we undertook a systematic review to examine the evidence for genetic variation being associated with secondary metabolic outcomes in patients with schizophrenia on clozapine, under both longitudinal and cross-sectional study designs. |
2018-05-22 |
2023-08-13 |
Not clear |
| K Sarathy, C Alexopoulo. A successful re-trial after clozapine myopericarditis. The journal of the Royal College of Physicians of Edinburgh. vol 47. issue 2. 2018-05-21. PMID:28675186. |
clozapine is also the most efficacious agent in refractory schizophrenia. |
2018-05-21 |
2023-08-13 |
Not clear |
| Conrad Molins, Mar Carceller-Sindreu, Helena Navarro, Cristina Carmona, Marina Piñeiro, Estrella Martínez, Enric Álvarez, Maria J Portell. Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients. Psychiatry research. vol 258. 2018-05-10. PMID:29024893. |
nineteen clinically stable patients with schizophrenia or schizoaffective disorder treated with clozapine monotherapy completed demographic and clinical interviews. |
2018-05-10 |
2023-08-13 |
Not clear |
| Ximena López Hill, Analía Richeri, María Cecilia Scorz. Clozapine blockade of MK-801-induced learning/memory impairment in the mEPM: Role of 5-HT Physiology & behavior. vol 179. 2018-05-01. PMID:28705535. |
clozapine blockade of mk-801-induced learning/memory impairment in the mepm: role of 5-ht cognitive impairment associated with schizophrenia (cias) is highly prevalent and affects the overall functioning of patients. |
2018-05-01 |
2023-08-13 |
Not clear |
| Vanteemar S Sreeraj, Damodaran Dinakaran, Sachin Nagendrappa, Naren P Rao, Muralidaran Kesavan, Shivarama Varambally, Ganesan Venkatasubramania. Clozaphobia: Is avoidance of clozapine in diabetes warranted? Asian journal of psychiatry. vol 28. 2018-04-27. PMID:28784368. |
in conclusion, a critique on the potential risks versus benefits of clozapine amidst our observations from this case series adds further supporting evidence to the emerging literature on the clinical utility of clozapine in treating schizophrenia patients with diabetes mellitus. |
2018-04-27 |
2023-08-13 |
Not clear |
| Jaime M Monti, Pablo Torterolo, Seithikurippu R Pandi Peruma. The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia. Sleep medicine reviews. vol 33. 2018-04-24. PMID:27321864. |
furthermore, administration of clozapine, olanzapine and paliperidone to patients with schizophrenia was followed in most instances by a significant reduction of sl and an increase of tst and se. |
2018-04-24 |
2023-08-13 |
human |
| Jaime M Monti, Pablo Torterolo, Seithikurippu R Pandi Peruma. The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia. Sleep medicine reviews. vol 33. 2018-04-24. PMID:27321864. |
taken together, this evidence supports the conclusion that second generation antipsychotics (sgas) including clozapine, olanzapine and paliperidone may ameliorate insomnia in patients with schizophrenia. |
2018-04-24 |
2023-08-13 |
human |
| Sarah M Norman, Kelli M Sullivan, Fang Liu, Bethany A DiPaula, Pedro A Jose, Christopher A Kitchen, Stephanie M Feldman, Deanna L Kell. Blood Pressure and Heart Rate Changes During Clozapine Treatment. The Psychiatric quarterly. vol 88. issue 3. 2018-04-23. PMID:27678498. |
clozapine (clz) is the gold standard of treatment for refractory schizophrenia. |
2018-04-23 |
2023-08-13 |
Not clear |
| S A J de With, S L Pulit, W G Staal, R S Kahn, R A Ophof. More than 25 years of genetic studies of clozapine-induced agranulocytosis. The pharmacogenomics journal. vol 17. issue 4. 2018-04-20. PMID:28418011. |
clozapine is one of the most effective atypical antipsychotic drugs prescribed to patients with treatment-resistant schizophrenia. |
2018-04-20 |
2023-08-13 |
human |
| Frederick C Nucifora, Marina Mihaljevic, Brian J Lee, Akira Saw. Clozapine as a Model for Antipsychotic Development. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. vol 14. issue 3. 2018-04-17. PMID:28653280. |
developing a medication as efficacious as clozapine with limited side effects would likely become the first-line therapy for schizophrenia and related disorders. |
2018-04-17 |
2023-08-13 |
Not clear |
| Maurizio Pompili, Laura Orsolini, Dorian A Lamis, David R Goldsmith, Adele Nardella, Giulia Falcone, Valentina Corigliano, Mario Luciano, Andrea Fiorill. Suicide Prevention in Schizophrenia: Do Long-Acting Injectable Antipsychotics (LAIs) have a Role? CNS & neurological disorders drug targets. vol 16. issue 4. 2018-04-16. PMID:28240189. |
clozapine is the only compound that gathered evidence as an effective treatment for reducing suicide risk in schizophrenia. |
2018-04-16 |
2023-08-13 |
Not clear |
| Oddur Ingimarsson, James H MacCabe, Magnús Haraldsson, Halldóra Jónsdóttir, Engilbert Sigurdsso. Risk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in Iceland. Nordic journal of psychiatry. vol 71. issue 7. 2018-04-10. PMID:28632422. |
risk of diabetes and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in iceland. |
2018-04-10 |
2023-08-13 |
Not clear |